Literature DB >> 7947361

Post-myocardial infarction ventricular remodeling: animal and human studies.

D E Vaughan1, M A Pfeffer.   

Abstract

Segmental alterations in left ventricular function are generally present in patients who suffer an acute myocardial infarction. Regional wall motion abnormalities in left ventricular systolic function can be identified in the hyperacute period and generally persist in patients who complete a myocardial infarction. Through the process of infarct expansion, the infarcted territory may thin and lengthen in the short term following a myocardial infarction. Some infarct survivors are also prone to further progressive alterations in the shape and size of the left ventricle, a process that has been termed postinfarction ventricular remodeling. Although left ventricular remodeling appears to represent an adaptive process serving to preserve stroke volume (and cardiac output) following myocardial injury, the enlargement process may have undesirable long-term effects on global left ventricular function and on clinical prognosis. Fortunately, recent experimental and clinical evidence demonstrates that ventricular remodeling and its deleterious consequences may be preventable.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947361     DOI: 10.1007/bf00877922

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  46 in total

1.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Authors:  M A Pfeffer; G A Lamas; D E Vaughan; A F Parisi; E Braunwald
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

2.  Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.

Authors:  N Sharpe; J Murphy; H Smith; S Hannan
Journal:  Lancet       Date:  1988-02-06       Impact factor: 79.321

3.  A randomized prospective trial of intravenous nitroglycerin in patients with acute myocardial infarction.

Authors:  J T Flaherty; L C Becker; B H Bulkley; J L Weiss; G Gerstenblith; C H Kallman; K J Silverman; J Y Wei; B Pitt; M L Weisfeldt
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

4.  A hemodynamic study of left ventricular aneurysm.

Authors:  M D Klein; M V Herman; R Gorlin
Journal:  Circulation       Date:  1967-04       Impact factor: 29.690

5.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; P W Brandt; R M Whitlock; C J Wild
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

6.  Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function.

Authors:  P J Fletcher; J M Pfeffer; M A Pfeffer; E Braunwald
Journal:  Circ Res       Date:  1981-09       Impact factor: 17.367

7.  Infarct expansion: pathologic analysis of 204 patients with a single myocardial infarct.

Authors:  J S Pirolo; G M Hutchins; G W Moore
Journal:  J Am Coll Cardiol       Date:  1986-02       Impact factor: 24.094

8.  Left ventricular failure induced by myocardial infarction. I. Myocyte hypertrophy.

Authors:  P Anversa; A V Loud; V Levicky; G Guideri
Journal:  Am J Physiol       Date:  1985-06

9.  A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction.

Authors:  E G Nabel; E J Topol; A Galeana; S G Ellis; E R Bates; S W Werns; J A Walton; D W Muller; M Schwaiger; B Pitt
Journal:  J Am Coll Cardiol       Date:  1991-02       Impact factor: 24.094

10.  Plasma atrial natriuretic peptide in patients with acute myocardial infarction: effects of streptokinase.

Authors:  P A Phillips; J Sasadeus; G P Hodsman; J Horowitz; A Saltups; C I Johnston
Journal:  Br Heart J       Date:  1989-02
View more
  3 in total

1.  Nipradilol, a new beta-adrenergic blocker, reduces left ventricular remodeling following myocardial infarction in spontaneously hypertensive rats.

Authors:  H Sonoki; M Nakamura; A Takeshita
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

2.  MicroRNAs as pathophysiological targets: An emerging nexus for personalized medicine in heart failure?

Authors:  Mark W Feinberg
Journal:  Trends Cardiovasc Med       Date:  2015-06-12       Impact factor: 6.677

3.  Effects of treatment with a 5-HT4 receptor antagonist in heart failure.

Authors:  J A K Birkeland; I Sjaastad; T Brattelid; E Qvigstad; E R Moberg; K A Krobert; R Bjørnerheim; T Skomedal; O M Sejersted; J-B Osnes; F O Levy
Journal:  Br J Pharmacol       Date:  2006-12-11       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.